The Economic Times
English EditionEnglish Editionहिन्दी
| E-Paper
Search
+

Back on the growth wagon: Cipla is a favourite of analysts and this week's stock pick

Back on the growth wagon: Cipla is a favourite of analysts and this week's stock pick
Back on the growth wagon: Cipla is a favourite of analysts and this week's stock pick
Improving domestic prospects and increasing sales from the US and South Africa raise hopes for the counter.

Synopsis

Cipla reported an FCF of around Rs 3,400 crore in 2019-20 and is expected to report bigger numbers in the coming years due to increased growth rates and cost savings due to domestic synergies. This has made the company a favourite of analysts.

Cipla, the domestic market leader in respiratory and urology segments, did well during the second quarter of 2020-21. It reported y-o-y revenue and adjusted net profit growth of 15% and 41% respectively in this time period. Cipla has eight medicine brands amongst top 100 domestic brands and 22 among top 300 brands. This strong brand power has helped it to report domestic numbers better than the industry average.Cipla is expected to report good
Share This Article
  • GIFT ARTICLE
  • FONT SIZE
  • SAVE
  • COMMENT

Sign in to read the full article

You’ve got this Prime Story as a Free Gift

Why ?

  • Sharp Insight-rich, Indepth stories across 20+ sectors

  • Access the exclusive Economic Times stories, Editorial and Expert opinion

  • Clean experience with
    Minimal Ads
  • Comment & Engage with ET Prime community
  • Exclusive invites to Virtual Events with Industry Leaders
  • A trusted team of Journalists & Analysts who can best filter signal from noise
The Economic Times